tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 297 are a BUY (85.34%), 50 are a HOLD (14.37%), 1 are a SELL (0.29%).
Analyst Robyn Karnauskas, currently employed at TRUIST, carries an average stock price target met ratio of 49.97% that have a potential upside of 42.11% achieved within 286 days.
Robyn Karnauskas’s has documented 708 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 08-Jan-2025.
Analyst best performing recommendations are on NCNA (NUCANA PLC).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$13.92 (7.28%)
$215
1 months 4 days ago
(14-May-2025)
12/14 (85.71%)
$27.59 (15.55%)
285
Buy
$216
$24.92 (13.04%)
$214
1 months 20 days ago
(29-Apr-2025)
23/26 (88.46%)
$22.49 (11.62%)
431
Buy
$250
$58.92 (30.84%)
$241
1 months 21 days ago
(28-Apr-2025)
12/18 (66.67%)
$57.66 (29.98%)
526
Buy
$240
$48.92 (25.60%)
$210
3 months 13 days ago
(05-Mar-2025)
7/8 (87.5%)
$28.46 (13.45%)
474
Hold
$223
$31.92 (16.71%)
$191
3 months 14 days ago
(04-Mar-2025)
3/4 (75%)
$15.71 (7.58%)
443
Which stock is Robyn Karnauskas is most bullish on?
Which stock is Robyn Karnauskas is most reserved on?
What Year was the first public recommendation made by Robyn Karnauskas?
